Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Combining cell sorting technology with artificial intelligence, Japan-based ThinkCyte aims to discover novel high-value therapeutic cells, new functional genes, and novel drug candidates for itself and its partners worldwide.
With unmatched industry expertise, Dark Horse Consulting provides strategic and technical services to help clients realize their goals of bringing therapies to patients and commercialization. Those seeking services from Dark Horse Consulting range from biopharmaceutical companies to tools and tech providers to investment firms.
With vast experience in cell-based therapies, Minaris Regenerative Medicine has become a trusted global partner for clinical and commercial manufacturing of cell therapies.
Mustang Bio is developing next-generation CAR T and gene therapies for cancer and rare genetic diseases, with lead clinical programs in non-Hodgkin lymphoma, chronic lymphocytic leukemia, and X-linked severe combined immunodeficiency.
Revitope is developing conditionally activated, T cell–engaging, bispecific antibodies containing dual tumor-specific antigens and split T cell–targeting paratopes that are unique in their high tolerability. The company is now focused on advancing its therapies to deliver safer and more efficacious therapies especially in solid cancer settings.
Driven by its small molecule libraries, biotech company Anticancer Bioscience has identified a line of oncology programs that could work as single agents or combination therapies.
Alloy Therapeutics, a biotechnology ecosystem company, is committed to providing affordable and non-exclusive access to a portfolio of foundational tools and services for the drug discovery community. Alloy’s lead platform is ATX-Gx, the world’s first royalty-free humanized mouse discovery platform.
Singh Biotechnology is developing novel camelid–derived single domain antibodies that target key intracellular molecular switches in cancer. The technology has therapeutic applications beyond cancer, and the company is seeking partners to advance its assets from preclinical to commercialization.
With a unique ownership structure and stable long-term funding, Biomed Valley Discoveries fuels a virtuous circle of investment, profit and research for the benefit of patients with unmet medical needs.
Building on an evolutionary ruse to cross the physiological blood–brain barrier, NEUWAY Pharma’s engineered protein capsules (EnPC) are poised to usher in a new era of effective CNS therapies.